Luteinizing hormone-releasing hormone agonists: A quick reference for prevalence rates of potential adverse effects

Clinical Genitourinary Cancer

Volumn 11, Issue 4, 2013, Pages 375-384

  Walker, Lauren M ^a,b   Tran, Susan ^a,b   Robinson, John W ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Androgen deprivation therapy; Continuing medical education; LHRH agonist; Prostate cancer; Side effect

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

ADVERSE OUTCOME; ANDROGEN DEPRIVATION THERAPY; BONE PAIN; BREAST TENDERNESS; DEPRESSION; DIARRHEA; DYSPNEA; ERECTILE DYSFUNCTION; EVIDENCE BASED PRACTICE; HUMAN; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; NIGHT SWEAT; OSTEOPENIA; OSTEOPOROSIS; PATIENT EDUCATION; PREVALENCE; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SARCOPENIA; SEXUAL DYSFUNCTION;

ANDROGEN DEPRIVATION THERAPY; CONTINUING MEDICAL EDUCATION; LHRH AGONIST; PROSTATE CANCER; SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DIETHYLSTILBESTROL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ESTROGENS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME;

EID: 84888008550     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2013.05.004     Document Type: Review

References (119)

1. M.R. Smith Androgen deprivation therapy for prostate cancer: new concepts and concerns Curr Opin Endocrinol Diabetes Obes 14 2007 247 254
2. M.V. Meng, G.D. Grossfeld, and N. Sadetsky Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer Urology 60 2002 7 11
3. M.R. Cooperberg, G.D. Grossfeld, and D.P. Lubeck National practice patterns and time trends in androgen ablation for localized prostate cancer J Natl Cancer Inst 95 2003 981 989
4. R.G. Casey, N.M. Corcoran, and S.L. Goldenberg Quality of life issues in men undergoing androgen deprivation therapy: a review Asian J Androl 14 2012 226 231
5. P.J. Saylor, and M.R. Smith Metabolic complications of androgen deprivation therapy for prostate cancer J Urol 181 2009 1998 2006
6. D.V. Makarov, E.B. Humphreys, and L.A. Mangold The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy J Urol 179 2008 156 161
7. H. Templeton, and V. Coates Informational needs of men with prostate cancer on hormonal manipulation therapy Patient Educ Couns 49 2003 243 256
8. T. Soeyonggo, P. Warde, and N. Fleshner Information needs of men on androgen deprivation therapy BJU Int 109 2012 1503 1509
9. L.M. Walker, S. Tran, and R.J. Wassersug Patients and partners lack knowledge of androgen deprivation therapy side effects Urol Oncol 2012 Jan 25 [Epub ahead of print]
10. J.L. Phillips, R.J. Wassersug, and D.L. McLeod Systemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice Int J Clin Pract 66 2012 1189 1196
11. Ogah I, Wassersug RJ. How reliable are "reputable sources" for medical information on the Internet? The case of hormonal therapy to treat prostate cancer. Urol Oncol 2012 Nov 7, 2012; doi: 10.1016/j.urolonc.2012.08. 003. [Epub ahead of print].
12. P.W. Kantoff, P.R. Carroll, and A.V. D'Amico Prostate Cancer: Principles and Practice 2002 Lippincott Williams & Wilkins Philadelphia
13. F. Labrie, B. Candas, and J.L. Gomez Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60 2002 115 119
14. R.L. Leibowitz, and S.J. Tucker Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients Oncologist 6 2001 177 182
15. J.C. Bailar 3rd, and D.P. Byar Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo Cancer 26 1970 257 261
16. G. Norman, M.E. Dean, and R.E. Langley Parenteral estrogen in the treatment of prostate cancer: a systematic review Br J Cancer 98 2008 697 707
17. R.E. Langley, I.F. Godsland, and H. Kynaston Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer BJU Int 102 2008 442 445
18. J.L. Ockrim, E.-N. Lalani, and A.K. Kakkar Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism J Urol 174 2005 527 533
19. J. Ockrim, E.-N. Lalani, and P. Abel Therapy insight: parenteral estrogen treatment for prostate cancer - a new dawn for an old therapy Nat Clin Pract Oncol 3 2006 552 563
20. J.L. Ockrim, E.-N. Lalani, and M.E. Laniado Transdermal estradiol therapy for advanced prostate cancer - forward to the past? J Urol 169 2003 1735 1737
21. M.R. Smith, S.P. Boyce, and E. Moyneur Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer J Urol 175 2006 136 139
22. M.R. Smith, J.S. Finkelstein, and F.J. McGovern Changes in body composition during androgen deprivation therapy for prostate cancer J Clin Endocrinol Metab 87 2002 599 603
23. D.J. Storey, D.B. McLaren, and M.A. Atkinson Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy Ann Oncol 23 2012 1542 1549
24. M.R. Smith, H. Lee, and F. McGovern Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome Cancer 112 2008 2188 2194
25. L.M. Eri, P. Urdal, and A.G. Bechensteen Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia J Urol 154 1995 100 104
26. M.R. Smith, H. Lee, and D.M. Nathan Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 2006 1305 1308
27. M.J. Lage, B.L. Barber, and R.A. Markus Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer Urology 70 2007 1104 1108
28. E.D. Crawford, M.A. Eisenberger, and D.G. McLeod A controlled trial of leuprolide with and without flutamide in prostatic carcinoma N Engl J Med 321 1989 419 424
29. P. Karling, M. Hammar, and E. Varenhorst Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma J Urol 152 1994 1170 1173
30. W. Oosterlinck, J. Casselman, and J. Mattelaer Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients Eur Urol 30 1996 458 463
31. A.L. Potosky, K. Knopf, and L.X. Clegg Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study J Clin Oncol 19 2001 3750 3757
32. D.A. Schow, L.G. Renfer, and T.A. Rozanski Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer South Med J 91 1998 855 857
33. T. Frodin, G. Alund, and E. Varenhorst Measurement of skin blood-flow and water evaporation as a means of objectively assessing hot flushes after orchidectomy in patients with prostatic cancer Prostate 7 1985 203 208
34. C.A. Engstrom Hot flashes in prostate cancer: state of the science Am J Mens Health 2 2008 122 132
35. E.A. Grunfeld, A. Halliday, and P. Martin Andropause syndrome in men treated for metastatic prostate cancer: a qualitative study of the impact of symptoms Cancer Nurs 35 2012 63 69
36. E.W. Ulloa, R. Salup, and S.G. Patterson Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer Psychooncology 18 2009 598 605
37. T. Nishiyama, S. Kanazawa, and R. Watanabe Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy Int J Urol 11 2004 735 741
38. C.S. Higano, W. Ellis, and K. Russell Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study Urology 48 1996 800 804
39. R.J. Wassersug, and J. Oliffe The social context for psychological distress from iatrogenic gynecomastia with suggestions for its management J Sex Med 6 2009 989 1000
40. K.K. Park, S.H. Lee, and B.H. Chung The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: a single-center, prospective, open-label, observational study J Sex Med 8 2011 3214 3219
41. A. Haliloglu, S. Baltaci, and O. Yaman Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer J Urol 177 2007 128 130
42. S. Elliott, D.M. Latini, L.M. Walker ADT Survivorship Working Group Androgen deprivation therapy for prostate cancer: recommendations to improve quality of life J Sex Med 7 2010 2996 3010
43. E. Ng, H.H. Woo, and S. Turner The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression J Urol 187 2012 2162 2166
44. F.J. Fowler Jr., M. McNaughton Collins, and E. Walker Corkery The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma Cancer 95 2002 287 295
45. T. Zaider, S. Manne, and C. Nelson Loss of masculine identity, marital affection, and sexual bother in men with localized prostate cancer J Sex Med 9 2012 2724 2732
46. M. Moyad Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review process for your patients Urol Oncol 23 2005 56 64
47. E.F. Yee, R.E. White, and G.H. Murata Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy J Gen Intern Med 22 2007 1305 1310
48. A. Wilcox, M.L. Carnes, and T.D. Moon Androgen deprivation in veterans with prostate cancer: implications for skeletal health Ann Pharmacother 40 2006 2107 2114
49. J. Morote, J.P. Morin, and A. Orsola Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer Urology 69 2007 500 504
50. V.B. Shahinian, Y.F. Kuo, and J.L. Freeman Risk of fracture after androgen deprivation for prostate cancer N Engl J Med 352 2005 154 164
51. S.B. Strum, J.E. McDermed, and M.C. Scholz Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade Br J Urol 79 1997 933 941
52. M.R. Smith, M. Goode, and A.L. Zietman Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition J Clin Oncol 22 2004 2546 2553
53. M. Braga-Basaria, A.S. Dobs, and D.C. Muller Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy J Clin Oncol 24 2006 3979 3983
54. F. Dockery, C.J. Bulpitt, and S. Agarwal Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia Clin Sci (Lond) 104 2003 195 201
55. J.C. Smith, S. Bennett, and L.M. Evans The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer J Clin Endocrinol Metab 86 2001 4261 4267
56. R.J. Kumar, A. Barqawi, and E.D. Crawford Adverse events associated with hormonal therapy for prostate cancer Rev Urol 7 suppl 5 2005 S37 S43
57. P. Famili, J.A. Cauley, and S.L. Greenspan The effect of androgen deprivation therapy on periodontal disease in men with prostate cancer J Urol 177 2007 921 924
58. F.E. Calais da Silva, A.V. Bono, and P. Whelan Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269 1277
59. N. Bruchovsky, L. Klotz, and J. Crook Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer Clin Genitourin Cancer 6 2008 46 52
60. M.K. Brawer Hormonal therapy for prostate cancer Rev Urol 8 suppl 2 2006 S35 S47
61. S.G. Mohile, M. Lacy, and M. Rodin Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer Crit Rev Oncol Hematol 75 2010 152 159
62. H.S. Kim, D.M. Moreira, and M.R. Smith A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database BJU Int 107 2011 924 928
63. F. Haseen, L.J. Murray, and C.R. Cardwell The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis J Cancer Surviv 4 2010 128 139
64. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 240 246
65. S.M. Alibhai, M. Duong-Hua, and R. Sutradhar Impact of androgen deprivation therapy on cardiovascular disease and diabetes J Clin Oncol 27 2009 3452 3458
66. I.H. Derweesh, C.J. DiBlasio, and M.C. Kincade Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer BJU Int 100 2007 1060 1066
67. J.P. Despres, B. Lamarche, and P. Mauriege Hyperinsulinemia as an independent risk factor for ischemic heart disease N Engl J Med 334 1996 952 957
68. A.V. D'Amico, J. Manola, and M. Loffredo 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial JAMA 292 2004 821 827
69. C.S. Saigal, J.L. Gore, and T.L. Krupski Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer Cancer 110 2007 1493 1500
70. L.G. Taylor, S.E. Canfield, and X.L. Du Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer Cancer 115 2009 2388 2399
71. H.K. Tsai, A.V. D'Amico, and N. Sadetsky Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516 1524
72. S. Punnen, M.R. Cooperberg, and N. Sadetsky Androgen deprivation therapy and cardiovascular risk J Clin Oncol 29 2011 3510 3516
73. P.L. Nguyen, Y. Je, and F.A. Schutz Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials JAMA 306 2011 2359 2366
74. M.A. Moyad, and M. Roach 3rd Promoting wellness for patients on androgen deprivation therapy: why using numerous drugs for drug side effects should not be first-line treatment Urol Clin North Am 38 2011 303 312
75. A. Berruti, L. Dogliotti, and C. Terrone Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy J Urol 167 2002 2361 2367
76. M.M. Cherrier, S. Aubin, and C.S. Higano Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non-metastatic prostate cancer Psychooncology 18 2009 237 247
77. A. Saini, A. Berruti, and C. Cracco Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy Urol Oncol 31 2013 352 358
78. C.J. DiBlasio, J. Hammett, and J.B. Malcolm Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer Can J Urol 15 2008 4249 4256
79. N. Timilshina, H. Breunis, and S.M. Alibhai Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer Cancer 118 2012 1940 1945
80. W.F. Pirl, J.A. Greer, and M. Goode Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy Psychooncology 17 2008 148 153
81. J.P. van Melle, P. de Jonge, and T.A. Spijkerman Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis Psychosom Med 66 2004 814 822
82. C. Kan, N. Silva, and S.H. Golden A systematic review and meta-analysis of the association between depression and insulin resistance Diabetes Care 36 2013 480 489
83. H.J. Green, K.I. Pakenham, and B.C. Headley Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial BJU Int 90 2002 427 432
84. V.A. Jenkins, D.J. Bloomfield, and V.M. Shilling Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study BJU Int 96 2005 48 53
85. S.M. Alibhai, S. Mahmouda, and F. Hussain Level of sex hormones have limited effect on cognition in older men with or without prostate cancer Crit Rev Oncol Hematol 73 2010 167 175
86. F. Joly, S.M. Alibhai, and J. Galica Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer J Urol 176 2006 2443 2447
87. L.M. Walker, and J.W. Robinson A description of heterosexual couples' sexual adjustment to androgen deprivation therapy for prostate cancer Psychooncology 20 2011 880 888
88. L. Navon, and A. Morag Advanced prostate cancer patients' ways of coping with the hormonal therapy's effect on body, sexuality, and spousal ties Qual Health Res 13 2003 1378 1392
89. L.M. Walker, and J.W. Robinson Sexual adjustment to androgen deprivation therapy: struggles and strategies Qual Health Res 22 2012 452 465
90. G. Corona, V. Boddi, and M. Gacci Perceived ejaculate volume reduction in patients with erectile dysfunction: psychobiologic correlates J Androl 32 2011 333 339
91. S.K. Steginga, S. Occhipinti, and J. Dunn The supportive care needs of men with prostate cancer (2000) Psychooncology 10 2001 66 75
92. A. Heidenreich Improving flexibility and quality of life for your patients: a must? Eur Urol Suppl 8 2009 857 862
93. Tran S, Walker LM, Wassersug RJ, et al. What do Canadian physicians believe patients should know about androgen deprivation therapy? J Oncol Pharm Pract In press.
94. S.G. Mohile, K. Mustian, and K. Bylow Management of complications of androgen deprivation therapy in the older man Crit Rev Oncol Hematol 70 2009 235 255
95. T.W. Flaig, and L.M. Glode Management of the side effects of androgen deprivation therapy in men with prostate cancer Expert Opin Pharmacother 9 2008 2829 2841
96. M. Grossmann, and J.D. Zajac Management of side effects of androgen deprivation therapy Endocrinol Metab Clin North Am 40 2011 655 671
97. M. Grossmann, and J.D. Zajac Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) 74 2011 289 293
98. H.S. Kim, and S.J. Freedland Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management Curr Opin Support Palliat Care 4 2010 147 152
99. E. Wibowo, P. Schellhammer, and R.J. Wassersug Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy J Urol 185 2011 17 23
100. R. Kacker, A.M. Traish, and A. Morgentaler Estrogens in men: clinical implications for sexual function and the treatment of testosterone deficiency J Sex Med 9 2012 1681 1696
101. Wibowo E, Wassersug RJ. The effect of estrogen on the sexual interest of castrated males: implications to prostate cancer patients on androgen-deprivation therapy. Crit Rev Oncol Hematol 2013 Feb 25. doi: 10.1016/j.critrevonc.2013.01.006. [Epub ahead of print].
102. R.H. Matousek, and B.B. Sherwin A randomized controlled trial of add-back estrogen or placebo on cognition in men with prostate cancer receiving an antiandrogen and a gonadotropin-releasing hormone analog Psychoneuroendocrinology 35 2010 215 225
103. C.C. Schulman Intermittent hormone therapy: what is its place in clinical practice? Eur Urol Suppl 8 2009 852 856
104. J.M. Crook, C.J. O'Callaghan, and G. Duncan Intermittent androgen suppression for rising PSA level after radiotherapy N Engl J Med 367 2012 895 903
105. L. Klotz, and P. Toren Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care? Curr Oncol 19 suppl 3 2012 S13 S21
106. A.J. Salonen, K. Taari, and M. Ala-Opas Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects Eur Urol 63 2013 111 120
107. E.Y. Yu, K.F. Kuo, and R. Gulati Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer J Clin Oncol 30 2012 1864 1870
108. C. Kelly, P. Kelly, and S. O'Reilly Intermittent androgen suppression for rising PSA level N Engl J Med 367 2012 2252 2253
109. M. Hussain, C.M. Tangen, and D.L. Berry Intermittent versus continuous androgen deprivation in prostate cancer N Engl J Med 368 2013 1314 1325
110. M. Gleave, L. Klotz, and S.S. Taneja The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer Urol Oncol 27 2009 81 86
111. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117 1123
112. N.J. Clegg, J. Wongvipat, and J.D. Joseph ARN-509: a novel antiandrogen for prostate cancer treatment Cancer Res 72 2012 1494 1503
113. G.R. Macvicar, and M.H. Hussain Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer Curr Opin Oncol 25 2013 252 260
114. H.I. Scher, T.M. Beer, and C.S. Higano Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
115. H.I. Scher, K. Fizazi, and F. Saad Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
116. N. Sharifi Minireview: androgen metabolism in castration-resistant prostate cancer Mol Endocrinol 27 2013 708 714
117. J.S. de Bono, C.J. Logothetis, and A. Molina Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
118. C.J. Ryan, M.R. Smith, and J.S. de Bono Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
119. K.O. Rove, and E.D. Crawford Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer Curr Opin Urol 23 2013 208 213